Opioids With Abuse-Deterrent Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
Only two of the six ER/LA opioids approved with abuse-deterrent labeling target the oral route of abuse.
You may also be interested in...
If Egalet Wins At FDA, Arymo ER Still Might Not In Opioid Market
Potential sales impact of even broadest possible label for oral, intranasal and intravenous abuse remains a question mark given that abuse-deterrent products remain only a small percentage of market.
FDA Panel Nod For Egalet Opioid's Deterrence Claims Made Easier By Tablet Hardness
Inability to chew Arymo ER tablet helps Egalet overcome questions about clinical meaningfulness of human oral abuse study results; advisors also back intranasal, intravenous deterrence claims.
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Drug liking score in human oral abuse study shows small but statistically significant difference, and clinical relevance is unclear, FDA says in advisory committee briefing documents.